WHO Updates GLP-1 Guidelines: Tirzepatide and Semaglutide for Obesity Management

Executive Brief

News Report

The News: WHO updates guidelines on GLP-1 medications for obesity management.
Clinical Win: Emphasizes the roles of tirzepatide and semaglutide in effective weight loss.
Target Specialty: Endocrinology

Key Data at a Glance

Recommended GLP-1 medications: Tirzepatide, Semaglutide
Minimum weight loss: 5% in most patients
Exclusion criteria: Pregnant women

The World Health Organization (WHO) has released updated guidelines on the use of glucagon-like peptide-1 (GLP-1) medicines for obesity management, emphasizing the roles of tirzepatide and semaglutide. This update, announced on December 1, 2025, is significant for healthcare professionals as obesity continues to rise globally, affecting over a billion individuals and leading to severe health complications.

Clinical Context

Obesity is a chronic, relapsing condition characterized by excessive fat accumulation that poses health risks. It is associated with numerous comorbidities, including type 2 diabetes, cardiovascular diseases, and certain cancers. Current treatments primarily include lifestyle interventions and pharmacotherapy. GLP-1 receptor agonists, initially developed for diabetes management, have shown promise in promoting weight loss and improving metabolic health. Semaglutide and tirzepatide are leading medications in this class, demonstrating significant weight reduction in clinical trials. However, the high cost and potential side effects, such as gastrointestinal disturbances and rare conditions like non-arteritic anterior ischemic optic neuropathy (NAION), have raised concerns about their long-term use. The WHO guidelines aim to provide a structured approach to integrating these medications into obesity management strategies, balancing efficacy with safety and accessibility.

Key Findings

The WHO guidelines recommend the use of GLP-1 receptor agonists, including tirzepatide and semaglutide, for long-term obesity management in adults with a body mass index (BMI) of 30 or greater, excluding pregnant women.

Both tirzepatide and semaglutide have been shown to reduce body weight by at least 5% in the majority of patients, with some achieving more significant reductions when combined with lifestyle changes.

The guidelines highlight the importance of a multidisciplinary approach, incorporating dietary modifications, physical activity, and behavioral therapy alongside pharmacotherapy to optimize weight loss outcomes.

Safety & Tolerability

Safety considerations include monitoring for gastrointestinal side effects and the rare risk of NAION associated with semaglutide, prompting healthcare providers to educate patients on recognizing symptoms of vision changes.

What This Means for Clinical Practice

The updated WHO guidelines underscore the importance of GLP-1 receptor agonists in managing obesity, particularly in patients who have not achieved sufficient weight loss through lifestyle interventions alone. Clinicians should consider these medications as part of a comprehensive treatment plan, ensuring patients understand both the benefits and potential risks. The emphasis on a multidisciplinary approach reinforces the need for collaboration among healthcare providers to enhance patient outcomes. As the landscape of obesity management evolves, ongoing education and adaptation of clinical practices will be essential to meet the needs of this growing patient population. How will these guidelines influence your treatment strategies for obesity in clinical practice?

Clinical Perspective

Workflow: Clinicians should integrate GLP-1 medications into obesity management plans, ensuring patients are informed of risks and benefits.

Economics: The high cost of these medications necessitates consideration of healthcare system capabilities and patient access.

Patient Outcomes: A multidisciplinary approach is essential for optimizing weight loss and improving overall health outcomes in patients with obesity.

Dr. Amit Desai, Endocrinology

WHO Updates GLP-1 Guidelines: Tirzepatide and Semaglutide for Obesity Management

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in Adults with Obesity

FDA Approves Orforglipron for Weight Loss: Oral GLP-1 Option for Obesity

FDA Approves Tirzepatide for Weight Management: Dosing Differences Between Mounjaro and Zepbound

Verified HCP Portal